Ensign Peak Advisors Inc Boosts Stake in Schrödinger, Inc. (NASDAQ:SDGR)

Ensign Peak Advisors Inc boosted its position in shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Rating) by 223.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 39,540 shares of the company’s stock after purchasing an additional 27,300 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.06% of Schrödinger worth $988,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Schrödinger by 1.9% during the third quarter. BlackRock Inc. now owns 3,788,647 shares of the company’s stock worth $94,641,000 after purchasing an additional 69,962 shares in the last quarter. ARK Investment Management LLC boosted its position in Schrödinger by 27.5% during the third quarter. ARK Investment Management LLC now owns 3,764,707 shares of the company’s stock worth $94,042,000 after purchasing an additional 811,535 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Schrödinger by 449.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,409,777 shares of the company’s stock worth $60,196,000 after purchasing an additional 1,971,292 shares in the last quarter. State Street Corp boosted its position in Schrödinger by 7.3% during the second quarter. State Street Corp now owns 990,385 shares of the company’s stock worth $26,156,000 after purchasing an additional 67,036 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Schrödinger by 1,463.0% during the second quarter. Millennium Management LLC now owns 930,145 shares of the company’s stock worth $24,565,000 after purchasing an additional 870,635 shares in the last quarter. 68.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on SDGR shares. BMO Capital Markets decreased their target price on Schrödinger from $83.00 to $78.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 1st. Piper Sandler boosted their price target on Schrödinger from $86.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, January 19th. The Goldman Sachs Group initiated coverage on Schrödinger in a report on Monday, December 19th. They issued a “neutral” rating and a $23.00 price target for the company. Finally, Citigroup boosted their price target on Schrödinger from $48.00 to $51.00 and gave the stock a “buy” rating in a report on Tuesday, January 31st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.40.

Schrödinger Trading Down 5.4 %

Schrödinger stock opened at $23.47 on Monday. The firm has a market capitalization of $1.67 billion, a P/E ratio of -11.18 and a beta of 1.02. The stock has a fifty day moving average price of $23.12 and a 200 day moving average price of $22.70. Schrödinger, Inc. has a 52 week low of $15.85 and a 52 week high of $37.25.

Insider Activity at Schrödinger

In related news, CEO Ramy Farid sold 66,886 shares of the company’s stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $18.28, for a total value of $1,222,676.08. Following the completion of the transaction, the chief executive officer now directly owns 184,432 shares in the company, valued at $3,371,416.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.90% of the company’s stock.

Schrödinger Company Profile

(Get Rating)

Schrödinger, Inc, together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.